Author Archives: Charles Moore

Fanfare Entertainment And Muses Labs Partner To Create Alzheimer’s MEND Protocol App

Burlingame, California based mobile platform company Fanfare Entertainment has partnered with Muses Labs to help develop, optimize, and market a next-generation personalized combination therapy for treatment and prevention of Alzheimer’s disease. The MEND (metabolic enhancement for neurodegeneration) Protocol is designed to enable Alzheimer’s disease patients, their caregivers, family members, and…

Samsung Tunisia Volunteers Develop Alzheimer’s Phone App

Samsung Tomorrow, the Samsung Electronics Official Global Blog, reports that about a year ago Samsung Electronics Tunisia (SETN) marketing manager for mobile products Azer Jaafoura and several colleagues began developing a smartphone app for helping out Alzheimer’s Disease (AD) patients. “We wanted to make life easier for Alzheimer’s patients…

Alzheimer’s Disease Research, Ellison Foundation to Invest $6 Million in UW Medicine Precision Medicine Approach

Currently incurable, Alzheimer’s disease (AD) is projected by the Centers for Disease Control to afflict some 13.8 million people in the U.S. by 2050 if effective new treatments are not discovered. Already, millions of U.S. residents are living with severe, disabling, and progressively degenerative Alzheimer’s-related dementia. Dr. Thomas…

Bluvision And GTX Corp. Collaborate On SmartSole GPS-Enabled Monitor Insoles For Persons With Dementia, Autism

Ft. Lauderdale, Florida based Bluvision has announced a collaborative venture with wearable technologies innovator GTX Corp., a company that specializes in the development of personal location devices, to create solutions for location tracking those with memory cognitive disorders like Alzheimer’s and other forms of Dementia, as well as persons…

Biotech Startup Yumanity Therapeutics Launched To Develop New Therapies for Neurodegenerative Diseases Caused by Protein Misfolding

Biotech industry veteran Tony Coles, M.D. has launched a new startup — Cambridge, Massachusetts-based Yumanity Therapeutics. Founded in December 2014, the new company’s central focus is on drug discovery for diseases caused by a DNA anomaly called “protein misfolding.” Yumanity Therapeutics’ founders include by Dr. Coles, who is…

Aduhelm Approved